FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
Waldenstrom Macroglobulinemia
Waldenström Macroglobulinemia 2020 Year-End Update: Diagnosis and Treatment Considerations
A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
Case Report Details COVID-19 Reinfection in Immunocompromised Patient
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Ibrutinib Effectiveness in Symptomatic, Previously Treated Waldenström Macroglobulinemia
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow Up
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
Improving Survival in Younger Patients With Waldenström Macroglobulinemia
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
Long-Term Zanubrutinib Treatment Effective for Majority of Patients With Waldenström Macroglobulinemia
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
Head-to-Head: Zanubrutinib vs Ibrutinib in Waldenström Macroglobulinemia
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.
Elevated Risk for Cause-Specific Mortality in Waldenström Macroglobulinemia
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
- Loading...
Loading...
Loading... 
Loading...